New research presented at the Alzheimer's Association International Conference (AAIC) 2026 suggests that blood-based biomarker testing could significantly improve the accuracy of Alzheimer's disease diagnosis in everyday clinical practice. In a real-world study involving more than 1,300 patients and 165 physicians, researchers found that access to blood test results helped both primary care physicians and specialists diagnose Alzheimer's with approximately 90% accuracy. The test measures biomarkers associated with amyloid beta and phosphorylated tau, two proteins linked to the disease.
The findings indicate that blood testing may help close the gap between primary and specialty care, making accurate diagnosis more accessible to patients. After reviewing blood test results, physicians changed their diagnoses in roughly one-third of cases and adjusted clinical management plans for more than half of patients. The test was particularly valuable in helping primary care physicians confidently rule out Alzheimer's disease and explore other causes of cognitive symptoms.
Researchers and Alzheimer's Association leaders say these results could help reduce delays in diagnosis and improve access to appropriate care, especially as traditional diagnostic methods such as PET scans and spinal fluid analysis can be costly and less widely available. The Association is also developing additional guidance and resources to support the appropriate use of blood biomarker testing in clinical settings.
Read the full announcement and learn more about the Alzheimer's Association research.
